Interaction between skeletal muscle and adipose tissue through myostatin in pancreatic cancer patients

Pancreatic cancer is a lethal disease. Patients with pancreatic cancer typically experience significant weight loss, including skeletal muscle loss. Patients with pancreatic cancer who lose muscle are more vulnerable, which lowers their quality of life and makes treatment more difficult to tolerate. Notably, patients with obesity tend to experience more severe muscle loss and worse outcomes. Given that individuals with obesity tend to have higher levels of myostatin, a protein known to contribute to muscle loss, the goal of this study was to investigate how myostatin levels in blood are related to an individual with pancreatic cancer’s amounts of muscle and fat. Our findings confirmed that higher myostatin levels in blood were associated with increased amounts of muscle. Furthermore, we found that higher myostatin levels were related to greater abdominal fat loss over time, but myostatin levels were not related to changes in skeletal muscle. These findings provide important information about how myostatin relates to body composition in pancreatic cancer. Further research into the underlying mechanisms of this association is needed to determine if lowering blood levels of myostatin may be an effective treatment for weight loss in people with cancer.